Voleon Capital Management’s Roivant Sciences ROIV Stock Holding History

Voleon Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-62,062	Closed	-$1.72M	–	900
2026 Q1	$1.72M	Sell	62,062 -280,359	-82%	-$7.2M	0.04%	354
2025 Q4	$7.43M	Buy	342,421 +245,848	+255%	+$4.85M	0.16%	135
2025 Q3	$1.46M	Buy	+96,573	New	+$1.2M	0.04%	357

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Voleon Capital Management's ROIV Position: Q2 2026 in Review

Voleon Capital Management sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 62,062 shares — an estimated $1.72M sold.

Voleon Capital Management first reported a position in ROIV in Q3 2025 and held it in 3 quarters. The position peaked at $7.43M in Q4 2025. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Voleon Capital Management reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Voleon Capital Management sold 62,062 Roivant Sciences shares in Q2 2026, an estimated $1.72M.
Voleon Capital Management first reported a position in Roivant Sciences in Q3 2025 and held it in 3 quarters.
Voleon Capital Management's Roivant Sciences position peaked at $7.43M in Q4 2025.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.